×
About 2,835 results

ALLMedicine™ Hemophagocytic Lymphohistiocytosis Center

Research & Reviews  1,030 results

INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)
https://clinicaltrials.gov/ct2/show/NCT05277272

May 13th, 2022 - Hemophagocytic Lymphohistiocytosis (HLH) is a complex, hyperinflammatory syndrome resulting from the interplay of genetic predisposition and various environmental factors. Despite available treatment options for HLH, approximately 30% of patients ...

Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocyt...
https://doi.org/10.1002/hon.3014
Hematological Oncology; He L, Wang Y et. al.

May 9th, 2022 - Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative approach for primary hemophagocytic lymphohistiocytosis (pHLH), but data on adult patients are scarce. Here we present an 8-year experience on HSCT for adult pHLH to re...

A retrospective survey of patients who discontinued participation in the JPLSG HLH-2004...
https://doi.org/10.1007/s12185-022-03357-1 10.3389/fped.2016.00047 10.1532/IJH97.07012 10.1182/blood-2017-06-788349 10.1007/s12185-018-02572-z 10.1038/bmt.2012.244 10.1111/bjh.13461 10.1016/j.jaip.2018.05.031 10.1056/NEJMoa1911326 10.1016/s2352-3026(19)30156-5 10.1002/pbc.24039 10.1002/pbc.24980
International Journal of Hematology; Ono R, Sakamoto K et. al.

May 7th, 2022 - Although clinical trials have reported an improvement in the prognosis of hemophagocytic lymphohistiocytosis (HLH), current treatment outcomes are unsatisfactory, especially in severe cases. Most clinical trial patients with severe disease discont...

Macrophage activation syndrome in rheumatic disease: Clinical characteristics and progn...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075640
PloS One; Nam SH, Ahn SM et. al.

May 7th, 2022 - Macrophage activation syndrome (MAS) is a hyperinflammatory condition that is known to be secondary hemophagocytic lymphohistiocytosis (HLH) in patients with rheumatic disease. The aim of study was to evaluate the clinical manifestations and outco...

see more →

Guidelines  3 results

Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340087
Pediatric Blood & Cancer; Jordan MB, Allen CE et. al.

Jul 25th, 2019 - Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of pathologic immune activation, often associated with genetic defects of lymphocyte cytotoxicity. Though a distinctive constellation of features has been described for HLH, diagnosis remains ...

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.
https://doi.org/10.1182/blood.2018894618
Blood La Rosée P, Horne A et. al.

Apr 18th, 2019 - Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by aberrantly activated macrophages and cytotoxic T cells. The primary (genetic) form, caused by mutations affecting lymphocyte cytotoxicity and immune regulat...

Consensus recommendations for the diagnosis and management of hemophagocytic lymphohist...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004414
Haematologica Lehmberg K, Nichols KE et. al.

Aug 28th, 2015 - The hyperinflammatory syndrome hemophagocytic lymphohistiocytosis can occur in the context of malignancies. Malignancy-triggered hemophagocytic lymphohistiocytosis should be regarded separately from hemophagocytic lymphohistiocytosis during chemot...

see more →

Drugs  8 results see all →

Clinicaltrials.gov  21 results

INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)
https://clinicaltrials.gov/ct2/show/NCT05277272

May 13th, 2022 - Hemophagocytic Lymphohistiocytosis (HLH) is a complex, hyperinflammatory syndrome resulting from the interplay of genetic predisposition and various environmental factors. Despite available treatment options for HLH, approximately 30% of patients ...

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
https://clinicaltrials.gov/ct2/show/NCT05001737

Apr 14th, 2022 - Study NI-0501-14 is a two-cohort trial that enrolls subjects who are diagnosed with sHLH/MAS (MAS being a form of secondary HLH) and who are presenting an inadequate response to high doses of GCs. These subjects will be enrolled in 2 cohorts as pe...

Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
https://clinicaltrials.gov/ct2/show/NCT05137522

Nov 30th, 2021 - This study aimed to investigate the efficacy and safety of Chidamide together with Etoposide and methylprednisolone for hemophagocytic lymphohistiocytosis

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
https://clinicaltrials.gov/ct2/show/NCT05008666

Aug 17th, 2021 - ENKTL is a highly aggressive non-Hodgkin lymphoma closely related to EBV infection,and advanced patients often suffer from hemophagocytic lymphohistiocytosis (HLH). ENKTL-HLH lacks standard treatment and experiences a extremely poor prognosis. An...

Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)
https://clinicaltrials.gov/ct2/show/NCT03510650

Jul 14th, 2021 - The investigators will draw blood samples of 100 patients at the time of diagnosis (each 50 with suspected or diagnosed HLH/sepsis) to determine a cytokine panel (c reactive protein (CRP), procalcitonin (PCT), interleukin (IL) 1β, IL-6, IL-8, IL-1...

see more →

News  71 results

Cilta-cel Offers Durable Option for Heavily Pretreated Multiple Myeloma
https://www.onclive.com/view/cilta-cel-offers-durable-option-for-heavily-pretreated-multiple-myeloma

Mar 23rd, 2022 - THE FDA HAS APPROVED ciltacabtagene autoleucel (cilta-cel; Carvykti) for the treatment of adult patients with relapsed/refractory multiple myeloma, following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory a...

Second CAR T-Cell Therapy Approved for Myeloma
https://www.medpagetoday.com/hematologyoncology/myeloma/97437

Mar 1st, 2022 - The FDA approved ciltacabtagene autoleucel (cilta-cel; Carvykti), the second chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma, Janssen Pharmaceuticals announced. Ciltacabtagene autoleucel, a B-...

Cilta-Cel Demonstrates Durable Responses at 2 Years Across Multiple Subgroups in R/R Myeloma
https://www.onclive.com/view/cilta-cel-demonstrates-durable-responses-at-2-years-across-multiple-subgroups-in-r-r-myeloma

Jan 4th, 2022 - Data from a longer follow-up analysis of the phase 1/2 CARTITUDE-1 trial (NCT03548207) demonstrated that all evaluated subgroups of patients with relapsed/refractory multiple myeloma maintained durable responses with ciltacabtagene autoleucel (cil...

Recruitment to Phase 2 Trial Examining PDS0101 Triplet in HPV Cancers Temporarily Suspended
https://www.onclive.com/view/recruitment-to-phase-2-trial-examining-pds0101-triplet-in-hpv-cancers-temporarily-suspended

Oct 29th, 2021 - The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute (NCI)–led phase 2 trial (NCT04287868), which is evaluating a novel triplet combination co...

Dr. Neelapu on the Safety Profile of KTE-C19 in Patients With Lymphoma
https://www.onclive.com/view/dr-neelapu-on-the-safety-profile-of-ktec19-in-patients-with-lymphoma

Oct 6th, 2021 - Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cel...

see more →

Patient Education  1 results see all →